Trinity Biotech PLC
NASDAQ:TRIB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (0.5), the stock would be worth $1.41 (131% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.2 | $0.61 |
0%
|
| 3-Year Average | 0.5 | $1.41 |
+131%
|
| 5-Year Average | 1.1 | $2.91 |
+374%
|
| Industry Average | 3.6 | $9.17 |
+1 397%
|
| Country Average | 1.9 | $4.83 |
+689%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$12.2m
|
/ |
Oct 2025
$48.6m
|
= |
|
|
$12.2m
|
/ |
Dec 2025
$69.9m
|
= |
|
|
$12.2m
|
/ |
Dec 2026
$79.1m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| IE |
|
Trinity Biotech PLC
NASDAQ:TRIB
|
11.6m USD | 0.2 | -0.3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 16.5 | 58 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 3.6 | 26 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 4.9 | 37.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 3 | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 4.2 | 24.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 7.6 | 43.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 1.7 | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 10.5 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 1.9 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 5.9 | 21.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.8 |
| Median | 1.9 |
| 70th Percentile | 3.2 |
| Max | 3 099.8 |
Other Multiples
Trinity Biotech PLC
Glance View
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The company is headquartered in Bray, Wicklow. The firm's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. The company operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business.
